Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

GLP-1

MetabolicFDA approvedPubMed records: 5000count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O GLP-1 (Peptídeo Semelhante ao Glucagon tipo 1) na forma de semaglutida é o tratamento mais validado para perda de peso baseado em peptídeos. Aprovado pela FDA como Ozempic (diabetes) e Wegovy (obesidade), demonstra ~15% de perda de peso em ensaios clínicos de larga escala. Original in PT-BR

GLP-1 is catalogued under Metabolic. 10 Eagle articles in this library reference this compound.

Category
Metabolic
Research stage
FDA approved — FDA Aprovado (Ozempic / Wegovy) Original in PT-BR
PubMed records
5000 (count from PubMed, not curated)
Eagle articles on this compound
10 Eagle articles

Mechanism

Agonista do receptor GLP-1 — reduz apetite e melhora controle glicêmico Original in PT-BR

A semaglutida é um análogo do GLP-1 humano com 94% de homologia, modificado com um ácido graxo C-18 para se ligar à albumina plasmática (meia-vida ~7 dias vs minutos do GLP-1 nativo). Atua em múltiplos receptores GLP-1: no pâncreas (aumenta secreção de insulina glicose-dependente), no estômago (retarda esvaziamento gástrico), no hipotálamo (reduz apetite e aumenta saciedade), e no sistema cardiovascular (efeitos cardioprotetores). O retardo do esvaziamento gástrico combinado com a ação central no apetite produz redução calórica sustentada sem a sensação de privação típica de dietas. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
910463-68-2
Molecular formula
C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight
4113.58 g/mol
Sequence
Análogo modificado de GLP-1 (7-37) Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Solução aquosa tamponada (produto comercial pré-diluído) Original in PT-BR
Stability
36 meses não aberto (2-8°C). Após primeiro uso: 56 dias Original in PT-BR
Half-life
~7 dias (semaglutida) Original in PT-BR
Bioavailability
Alta (SC), oral disponível (Rybelsus) Original in PT-BR
Onset
1-2 semanas (saciedade), 4-8 semanas (perda de peso significativa) Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

98/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Redução de 26% em eventos cardiovasculares maiores (MACE) Original in PT-BR

    PMID: 28563169Year: 2017Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Perda de peso média de 14.9% vs 2.4% placebo em 68 semanas Original in PT-BR

    PMID: 33567185Year: 2021Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Meta-análise confirmando benefícios cardiovasculares e renais da classe Original in PT-BR

    PMID: 35658024Year: 2022Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Náusea (40-44% — diminui com o tempo)
  • Diarreia
  • Constipação
  • Dor abdominal
  • Vômitos

Serious

  • Pancreatite (raro mas grave)
  • Risco teórico de carcinoma medular de tireoide (roedores)
  • Colecistite/colelitíase

Contraindications

  • Histórico pessoal/familiar de carcinoma medular de tireoide
  • Neoplasia endócrina múltipla tipo 2 (MEN2)
  • Pancreatite crônica
  • Gravidez/amamentação

Warnings

  • Escalonamento gradual de dose obrigatório
  • Risco de hipoglicemia com sulfonilureias/insulina
  • Possível perda de massa magra sem exercício

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for GLP-1.

Lab tests named in the source

  • HbA1c
  • Glicemia de jejum
  • Perfil lipídico
  • Amilase/lipase
  • TSH
  • Função hepática

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Posologia
Depende da molécula e do produto — consulte a bula do produto específico Original in PT-BR

Vial sizes: 5mg — Peptide Calculator

Interactions

This section brings together two origins. The ones Eagle wrote come from its own curated library, one by one; the rest come from the imported reference material, which records one label and one comment per pair and no source. Neither kind carries a PMID, a population or model, or a degree of certainty. Eagle did not verify the imported ones and does not endorse them. «Compatible», «Caution» and «Avoid» are not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

Compatible

Caution

Avoid

Related

← Back to knowledge area